Your browser is no longer supported. Please, upgrade your browser.
THRX [NASD]
Theseus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-22.92 Insider Own4.90% Shs Outstand38.84M Perf Week-9.74%
Market Cap349.17M Forward P/E- EPS next Y-1.14 Insider Trans27.53% Shs Float37.44M Perf Month-18.94%
Income- PEG- EPS next Q-0.23 Inst Own65.60% Short Float3.04% Perf Quarter-44.06%
Sales- P/S- EPS this Y-67.00% Inst Trans- Short Ratio5.07 Perf Half Y-
Book/sh-44.02 P/B- EPS next Y33.30% ROA- Target Price25.00 Perf Year-
Cash/sh2.33 P/C3.86 EPS next 5Y- ROE- 52W Range8.17 - 24.54 Perf YTD-29.10%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-63.37% Beta-
Dividend %- Quick Ratio16.10 Sales past 5Y- Gross Margin- 52W Low10.04% ATR1.32
Employees13 Current Ratio16.10 Sales Q/Q- Oper. Margin- RSI (14)40.86 Volatility13.66% 12.39%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.44 Prev Close8.75
ShortableYes LT Debt/Eq- EarningsNov 15 BMO Payout- Avg Volume224.03K Price8.99
Recom1.20 SMA20-12.79% SMA50-27.89% SMA200-35.50% Volume98,828 Change2.74%
Nov-01-21Initiated Wedbush Outperform $24
Nov-01-21Initiated SVB Leerink Outperform $28
Nov-01-21Initiated Jefferies Buy $23
Nov-01-21Initiated Cantor Fitzgerald Overweight $25
Jan-07-22 09:07AM  
Dec-17-21 08:00AM  
Nov-15-21 07:00AM  
Nov-10-21 07:00AM  
Nov-01-21 01:54PM  
Oct-22-21 04:30PM  
Oct-15-21 08:43AM  
Oct-07-21 02:02PM  
Oct-06-21 10:20PM  
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-variant inhibitor for activating and resistance mutations of the KIT kinase or a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GORDON CARL LDirectorJan 21Buy9.97111,8961,115,60316,542,652Jan 21 07:22 PM
ORBIMED ADVISORS LLCDirectorJan 21Buy9.97111,8961,115,60316,542,652Jan 21 07:18 PM
GORDON CARL LDirectorJan 20Buy9.9535,000348,25016,430,756Jan 21 07:22 PM
ORBIMED ADVISORS LLCDirectorJan 20Buy9.9535,000348,25016,430,756Jan 21 07:18 PM
GORDON CARL LDirectorJan 19Buy9.9711,521114,86416,395,756Jan 21 07:22 PM
ORBIMED ADVISORS LLCDirectorJan 19Buy9.9711,521114,86416,395,756Jan 21 07:18 PM
GORDON CARL LDirectorJan 13Buy9.4317,320163,32816,384,235Jan 13 07:27 PM
ORBIMED ADVISORS LLCDirectorJan 13Buy9.4317,320163,32816,384,235Jan 13 07:18 PM
GORDON CARL LDirectorJan 12Buy10.0618,897190,10416,366,915Jan 13 07:27 PM
ORBIMED ADVISORS LLCDirectorJan 12Buy10.0618,897190,10416,366,915Jan 13 07:18 PM
GORDON CARL LDirectorJan 11Buy10.518,50089,31916,348,018Jan 13 07:27 PM
ORBIMED ADVISORS LLCDirectorJan 11Buy10.518,50089,31916,348,018Jan 13 07:18 PM
CLACKSON TIMOTHY PPresident and CEODec 21Buy9.762,60025,381348,530Dec 22 06:26 PM
Dahms Bradford D.Chief Financial OfficerDec 21Buy10.151,97020,0001,970Dec 22 06:21 PM